Nammex Introduces Lion’s Mane Mycelium Ingredient Through Partnership with Novelara

Nammex Mushrooms, a supplier specializing in certified organic functional mushroom extracts, has introduced ErinaPrime, a 100% pure freeze-dried lion’s mane mycelium powder, through a partnership with Novelara.

Other mycelium products on the market contain inseparable grain, which is used as a substrate. ErinaPrime contains only lion’s mane with no grain, and verified levels of Erinacine A, a clinically-studied neuroactive compound found exclusively in Lion’s Mane mycelium.

“Nammex has historically focused on organic mushroom extract powders because most mycelium ingredients on the market are mycelium fermented grain products with chemical profiles much closer to the grain substrate than to pure mycelium,” said Skye Chilton, CEO. “ErinaPrime is fundamentally different. It is 100% pure lion’s mane mycelium, standardized to 1% erinacine A, produced through a sophisticated submerged liquid fermentation process designed specifically to preserve and optimize these compounds. This ingredient is in a league of its own.”

ErinaPrime was developed with a production method specifically designed around compound expression, consistency, and analytical verification. The ingredient is cultivated through a proprietary submerged liquid fermentation process and processed post-harvest via precision freeze-drying to preserve the mycelium’s natural biochemical profile without the use of extraction or solvents.

“Protecting the integrity of the erinacines is paramount throughout the entire process,” said Chilton. “Mycelium is fragile, and consistently producing meaningful levels of erinacine A at a commercial scale requires specialized expertise in strain optimization, liquid culture fermentation, analytical verification, and quality assurance. Every stage of production is focused on preserving the biochemical composition and consistency of the mycelium.”

ErinaPrime is manufactured through a partnership with Nevelara and produced by Grape King Bio, which has mushroom research facilities, reference standard manufacturing laboratories, and analytical capabilities dedicated specifically to erinacine production and verification.

“There’s no shortcut to bringing a genuinely novel ingredient like ErinaPrime to market,” said Paul Eftang, CEO of Novelara. “We spent the better part of a decade building the scientific infrastructure to make this possible: a mushroom research facility, a reference standard manufacturing lab, and new analytical methods developed specifically to standardize erinacine A. Our partners at Grape King Bio built a state of the art liquid bioreactor facility capable of producing pure lion’s mane mycelium standardized to erinacine A at true commercial scale. Based on testing at Omnient Labs, ErinaPrime contains more than 90 times the erinacine A content of the average lion’s mane sample evaluated, underscoring just how differentiated this ingredient is from anything currently in the category.”

At a dose of 3 mg, erinacine A has been associated with improvements in neurocognitive health markers. ErinaPrime’s potency levels are verified through validated analytical testing conducted by an independent ISO/IEC 17025:2017 accredited laboratory.

ErinaPrime is supported by an ongoing research program; multiple human clinical trials have been conducted on the ingredient, with additional studies currently underway to expand the understanding of standardized lion’s mane mycelium and support more rigorous formulation development in the cognitive health category.

“We are partnering with Nammex to extend the reach of ErinaPrime and help push the mushroom ingredient category toward higher-quality, science-founded ingredients,” said Eftang. “Nammex has spent decades building trust through education, quality, and responsible commercialization, making them an ideal partner for bringing this next-generation lion’s mane ingredient to the broader market.”